BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 15755896)

  • 21. Selective usage of D-type cyclins in lymphoid malignancies.
    Suzuki R; Kuroda H; Komatsu H; Hosokawa Y; Kagami Y; Ogura M; Nakamura S; Kodera Y; Morishima Y; Ueda R; Seto M
    Leukemia; 1999 Sep; 13(9):1335-42. PubMed ID: 10482983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
    Gabrea A; Martelli ML; Qi Y; Roschke A; Barlogie B; Shaughnessy JD; Sawyer JR; Kuehl WM
    Genes Chromosomes Cancer; 2008 Jul; 47(7):573-90. PubMed ID: 18381641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
    Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
    J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
    Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
    Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias.
    Clappier E; Cuccuini W; Cayuela JM; Vecchione D; Baruchel A; Dombret H; Sigaux F; Soulier J
    Leukemia; 2006 Jan; 20(1):82-6. PubMed ID: 16270038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of D-type cyclins in normal and neoplastic rat pituitary.
    Qian X; Kulig E; Jin L; Lloyd RV
    Endocrinology; 1998 Apr; 139(4):2058-67. PubMed ID: 9528994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
    Tiedemann RE; Mao X; Shi CX; Zhu YX; Palmer SE; Sebag M; Marler R; Chesi M; Fonseca R; Bergsagel PL; Schimmer AD; Stewart AK
    J Clin Invest; 2008 May; 118(5):1750-64. PubMed ID: 18431519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
    Yang L; Wang H; Kornblau SM; Graber DA; Zhang N; Matthews JA; Wang M; Weber DM; Thomas SK; Shah JJ; Zhang L; Lu G; Zhao M; Muddasani R; Yoo SY; Baggerly KA; Orlowski RZ
    Oncogene; 2011 Mar; 30(11):1329-40. PubMed ID: 21057542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.
    Chinen Y; Tsukamoto T; Maegawa-Matsui S; Matsumura-Kimoto Y; Takimoto-Shimomura T; Tanba K; Mizuno Y; Fujibayashi Y; Kuwahara-Ota S; Shimura Y; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Exp Hematol; 2020 Apr; 84():45-53.e1. PubMed ID: 32145384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
    Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
    Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cyclins D-type in B-chronic lymphoproliferative disorders.
    Sola B; Roué G; Duquesne F; Avet-Loiseau H; Macro M; Salaün V; Troussard X
    Leukemia; 2000 Jul; 14(7):1318-9. PubMed ID: 10914560
    [No Abstract]   [Full Text] [Related]  

  • 33. New insights into the pathophysiology of multiple myeloma.
    Seidl S; Kaufmann H; Drach J
    Lancet Oncol; 2003 Sep; 4(9):557-64. PubMed ID: 12965277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
    Glassford J; Rabin N; Lam EW; Yong KL
    Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
    Cardona-Benavides IJ; Misiewicz-Krzeminska I; Rojas EA; De Ramón C; Sanz-Solas A; Isidro I; Quwaider D; López-Guerrero AM; Cuadrado M; Calasanz MJ; Rosiñol L; Martínez-López J; San Miguel JF; Mateos MV; Corchete LA; Gutiérrez NC
    Haematologica; 2024 Mar; 109(3):877-887. PubMed ID: 37646661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
    Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
    Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor.
    Faussillon M; Monnier L; Junien C; Jeanpierre C
    Cancer Lett; 2005 Apr; 221(1):67-75. PubMed ID: 15797629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pathogenesis of multiple myeloma: basic and clinical updates.
    Chesi M; Bergsagel PL
    Int J Hematol; 2013 Mar; 97(3):313-23. PubMed ID: 23456262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies.
    Raynaud SD; Bekri S; Leroux D; Grosgeorge J; Klein B; Bastard C; Gaudray P; Simon MP
    Genes Chromosomes Cancer; 1993 Oct; 8(2):80-7. PubMed ID: 7504521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.